Table 10.
GOG trials of hormone therapy in endometrial cancer.
| GOG study and dosing | RR (%) | PFS (months) | OS (months) | DOR (months) |
|---|---|---|---|---|
| 153 MA 80 mg BID × 3 weeks alternating with T 20 mg BID × 3 weeks | 27% | 2.7 months | 14.0 months | 28 months |
| 121 high dose MA 800 mg daily | 24% | 2.5 months | 7.6 months | 8.9 months |
| 81 MA high dose 1000 mg daily versus low dose 200 mg daily | 15% high dose 25% low dose |
2.5 months 3.2 months |
7.0 months 11.1 months |
NR |
| 119 T 200 mg BID + MPA 100 mg BID intermittently weekly | 33% | 3.0 months | 12.8 months | NR |
| 81F T 20 mg BID | 10% | 1.9 months | 8.8 months | NR |
MA: megastrol acetate; T: tamoxifen; MPA: medroxyprogesterone acetate; RR: response rate; PFS: progression free-survival (median); OS: overall survival (median); DOR: duration of response (median); NR: not reported.